B-cell non-Hodgkin lymphoma – Epidemiology – Americas

Clarivate Epidemiology’s coverage of B-cell non-Hodgkin lymphoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the incidence of B-cell non-Hodgkin lymphoma for each country, as well as annualized case counts projected to the national population. For most populations included in this report, we focus on the epidemiology of three major subtypes of B-cell non-Hodgkin lymphoma: FL, DLBCL, and MCL.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe and Japan, and 10 years for the other countries covered in this report. In addition to forecasting incident patient populations, the number of drug-treatment opportunities at specific lines of therapy are also forecast across the developed world for B-cell non-Hodgkin lymphoma subtypes.

Clarivate Epidemiology’s B-cell non-Hodgkin lymphoma forecast will answer the following questions:

• In developing countries, what impact will economic growth and development have on the number of people diagnosed with B-cell non-Hodgkin lymphoma per year?
• How will improvements in survival change the number of people living with a diagnosis of B-cell non-Hodgkin lymphoma subtypes?
• Of all people diagnosed with B-cell non-Hodgkin lymphoma subtypes, how many in each country across the developed world are drug-treated?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of B-cell non-Hodgkin lymphoma and its subtypes over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graphical depiction of the patient flow between or within different disease states for the countries considered in this report. These patient flow diagrams are provided at the regional level, but may be requested for any specific country or forecast year.

Clarivate Epidemiology forecasts B-cell non-Hodgkin lymphoma patient populations, as follows:

• Diagnosed B-cell NHL incident cases
• Diagnosed B-cell NHL incident cases by subtype (FL, DLBCL, MCL)
• Diagnosed NHL NOS incident cases
• Transformed incident cases – FL and CLL / SLL to DLBCL
• Diagnosed prevalent cases – FL, DLBCL, MCL
• Diagnosed FL incident cases by grade (FL grade 1, 2, 3A, 3B, 3 NOS, FL NOS)
• Diagnosed de novo DLBCL incident cases by cell of origin
• Stage distribution – FL, DLBCL, MCL
• Diagnosed 1st line drug-treatable population – FL, DLBCL, MCL
• Diagnosed 1st line drug-treated population – FL, DLBCL, MCL
• Diagnosed 2nd line drug-treatable population – FL, DLBCL, MCL
• Diagnosed 2nd line drug-treated population – FL, DLBCL, MCL
• … and many more (details available on request).

Note: coverage may vary by country.